Literature DB >> 12047733

Policy progress for physician treatment of opiate addiction.

Joseph O Merrill1.   

Abstract

Medical treatment of heroin addiction with methadone and other pharmacotherapies has important benefits for individuals and society. However, regulatory policies have separated this treatment from the medical care system, limiting access to care and contributing to the social stigma of even effective addiction pharmacotherapy. Increasing problems caused by heroin addiction have added urgency to the search for policies and programs that improve the access to and quality of opiate addiction treatment. Recent initiatives aiming to reintegrate methadone maintenance and other addiction pharmacotherapies into medical practice may promote both expanded treatment capacity and increased physician expertise in addiction medicine. These initiatives include changes in federal oversight of the opiate addiction treatment system, the approval of physician office-based methadone maintenance programs for stabilized patients, and federal legislation that could enable physicians to treat opiate addiction with new medications in regular medical practice.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12047733      PMCID: PMC1495048     

Source DB:  PubMed          Journal:  J Gen Intern Med        ISSN: 0884-8734            Impact factor:   5.128


  47 in total

1.  Treatment for opioid dependence: quality and access.

Authors:  B J Rounsaville; T R Kosten
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272

2.  Recent developments in maintenance prescribing and monitoring in the United Kingdom.

Authors:  C Brewer
Journal:  Bull N Y Acad Med       Date:  1995

3.  Methadone dosing, heroin affordability, and the severity of addiction.

Authors:  P B Bach; J Lantos
Journal:  Am J Public Health       Date:  1999-05       Impact factor: 9.308

4.  A 12-year follow-up of a methadone medical maintenance program.

Authors:  R P Schwartz; R K Brooner; I D Montoya; M Currens; M Hayes
Journal:  Am J Addict       Date:  1999

5.  Differences between general practitioner- and addiction centre-prescribed buprenorphine substitution therapy in France. Preliminary results.

Authors:  J Vignau; E Brunelle
Journal:  Eur Addict Res       Date:  1998       Impact factor: 3.015

6.  Moderate- vs high-dose methadone in the treatment of opioid dependence: a randomized trial.

Authors:  E C Strain; G E Bigelow; I A Liebson; M L Stitzer
Journal:  JAMA       Date:  1999-03-17       Impact factor: 56.272

7.  A randomized trial of buprenorphine maintenance for heroin dependence in a primary care clinic for substance users versus a methadone clinic.

Authors:  P G O'Connor; A H Oliveto; J M Shi; E G Triffleman; K M Carroll; T R Kosten; B J Rounsaville; J A Pakes; R S Schottenfeld
Journal:  Am J Med       Date:  1998-08       Impact factor: 4.965

8.  A MEDICAL TREATMENT FOR DIACETYLMORPHINE (HEROIN) ADDICTION. A CLINICAL TRIAL WITH METHADONE HYDROCHLORIDE.

Authors:  V P DOLE; M NYSWANDER
Journal:  JAMA       Date:  1965-08-23       Impact factor: 56.272

9.  Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial.

Authors:  K L Sees; K L Delucchi; C Masson; A Rosen; H W Clark; H Robillard; P Banys; S M Hall
Journal:  JAMA       Date:  2000-03-08       Impact factor: 56.272

Review 10.  Role of maintenance treatment in opioid dependence.

Authors:  J Ward; W Hall; R P Mattick
Journal:  Lancet       Date:  1999-01-16       Impact factor: 79.321

View more
  11 in total

1.  Substance abuse: the expanding role of general internal medicine.

Authors:  Patrick G O'Connor; Jeffrey H Samet
Journal:  J Gen Intern Med       Date:  2002-05       Impact factor: 5.128

2.  Access to publicly funded methadone maintenance treatment in two western states.

Authors:  Dennis Deck; Matthew J Carlson
Journal:  J Behav Health Serv Res       Date:  2004 Apr-Jun       Impact factor: 1.505

Review 3.  Acute pain management for patients receiving maintenance methadone or buprenorphine therapy.

Authors:  Daniel P Alford; Peggy Compton; Jeffrey H Samet
Journal:  Ann Intern Med       Date:  2006-01-17       Impact factor: 25.391

4.  Retention in publicly funded methadone maintenance treatment in two Western States.

Authors:  Dennis Deck; Matthew J Carlson
Journal:  J Behav Health Serv Res       Date:  2005 Jan-Mar       Impact factor: 1.505

5.  Methadone medical maintenance in primary care. An implementation evaluation.

Authors:  Joseph O Merrill; T Ron Jackson; Beryl A Schulman; Andrew J Saxon; Asaad Awan; Sonja Kapitan; Molly Carney; Lyndia C Brumback; Dennis Donovan
Journal:  J Gen Intern Med       Date:  2005-04       Impact factor: 5.128

6.  Characteristics of methadone maintenance treatment patients prescribed opioid analgesics.

Authors:  Matthew C Glenn; Nancy L Sohler; Joanna L Starrels; Jeronimo Maradiaga; John J Jost; Julia H Arnsten; Chinazo O Cunningham
Journal:  Subst Abus       Date:  2016-01-05       Impact factor: 3.716

7.  Variation in use of buprenorphine and methadone treatment by racial, ethnic, and income characteristics of residential social areas in New York City.

Authors:  Helena B Hansen; Carole E Siegel; Brady G Case; David N Bertollo; Danae DiRocco; Marc Galanter
Journal:  J Behav Health Serv Res       Date:  2013-07       Impact factor: 1.505

Review 8.  National Institute on Drug Abuse International Program: improving opioid use disorder treatment through international research training.

Authors:  Steven W Gust; Judy McCormally
Journal:  Curr Opin Psychiatry       Date:  2018-07       Impact factor: 4.741

9.  Integrating medical care and addiction treatment.

Authors:  Joseph O Merrill
Journal:  J Gen Intern Med       Date:  2003-01       Impact factor: 6.473

10.  Spillover effects of HIV testing policies: changes in HIV testing guidelines and HCV testing practices in drug treatment programs in the United States.

Authors:  Jemima A Frimpong; Thomas D'Aunno; Stéphane Helleringer; Lisa R Metsch
Journal:  BMC Public Health       Date:  2016-07-29       Impact factor: 3.295

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.